The DOI matches its Crossref record; 79 of the 83 references it cites were found in a registry or an index; 82 of the 155 sources its claims cite were checked for support.
The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors
Open accessAbstract
Testicular germ cell tumors (TGCTs) are cancers with very good prognosis, even in the metastatic setting, with high curative potential mainly attributed to the introduction of cisplatin-based chemotherapy. However, approximately 15% of the patients develop platinum-refractory disease and suffer multiple relapses. Therefore, there is an unmet need for novel therapeutic agents with improved efficacy and minimal long-term side effects. Recent advances in the development of immunotherapeutic agents, particularly immune checkpoint inhibitors (ICIs), have offered an opportunity to test their activity in various tumor types, including GCTs. This review aims to analyze the immune microenvironment of these tumors and present the most recently available data from studies that have tested immunotherapeutic agents against GCTs. The majority of the available knowledge derives from case reports or small cohort studies, particularly those involving ICIs of the PD-1/PD-L1 axis alone or in combination with anti-CTLA-4 monoclonal antibodies. Other immunotherapeutic targeted approaches, including antibody-drug conjugates, antibody prodrugs, vaccines, tyrosine kinase inhibitors, chimeric antigen receptor (CAR) T-cell therapy, have biological rationales and have shown preliminary activity or are currently being tested. Growing evidence on these and other approaches will assist in broadening the currently limited treatment armamentarium against platinum-refractory TGCTs.
Overview
CoChat Summary
## TL;DR
This is a systematic review of the immune microenvironment of testicular germ cell tumors (TGCTs) and the very limited clinical evidence for immunotherapy in platinum-refractory disease. The paper concludes that current immune checkpoint inhibitor results are mostly disappointing, but biomarker-driven trials and newer approaches such as antibody-drug conjugates, prodrugs, vaccines, and CAR-T cells may expand treatment options.
## Key findings
- Approximately 15% of patients with TGCTs develop platinum-refractory disease; the authors also state that one-fifth of patients with advanced TGCTs develop platinum-refractory disease.
- In a case series of 7 platinum-refractory patients treated with nivolumab or pembrolizumab, 4 died after a single dose, while 2 had long-term tumor response associated with high PD-L1 expression.
- In a phase II study of 12 cisplatin-refractory patients treated with pembrolizumab, there were no partial or complete responses; 2/12 had stable disease lasting 28 and 19 weeks.
- In a phase II study of 8 patients treated with avelumab, all progressed within 2.6 months; median PFS was 0.9 months and median OS was 2.7 months. A durvalumab ± tremelimumab trial enrolled 22 patients; the combination arm had 1 partial response and 1 stable disease with serologic improvement.
- For brentuximab vedotin, one study of 7 CD30-overexpressing patients reported 2 objective responses (1 complete, 1 partial), but a later 18-patient phase II study found no partial or complete responses; median PFS was 1.2 months in CD30-positive patients and 1.4 months in CD30-negative patients.
## Methods
- Design: Systematic review conducted according to PRISMA guidelines; the study was not registered.
- Data/sample: Literature search in PubMed and Web of Science using terms related to TGCTs, immunotherapy, PD-L1, CTLA-4, platinum-resistant, and platinum-refractory disease.
- Main analysis: Narrative synthesis of the immune landscape of TGCTs and the preclinical/clinical evidence for immunotherapeutic strategies, with emphasis on published case reports, small cohorts, and early-phase trials.
## Limitations
- The paper explicitly states that randomized data are largely absent in advanced TGCTs, and that the best available evidence comes from small cohort studies and case reports.
- The authors note that the review was not registered.
- Evidence for many emerging approaches is described as preliminary or based on biological rationale rather than definitive clinical proof (evident from the text).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
74 Valid · 4 Not valid · 55 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Median overall survival (OS) was 2.5 and 5 months in the CD30-positive and CD30-negative groups, respectively [56].”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 5. Immunotherapy in TGCTs > 5.2. Anti-CD30 Antibody-Drug Conjugate Therapy To identify novel therapeutic agents for patients with cisplatin-refractory disease and following the poor results of anti-PD-1/PD-L1 inhibitors in the management of these patients, the antibody-drug conjugate brentuximab vedotin was tested in clinical trials. This conjugate is composed of a chimeric antibody that is covalently linked to the cell-surface antigen CD30, and it is combined with the cytotoxic anti-tubulin agent monomethylauristatin E. In a phase II study, seven patients with multiple relapses or cisplatin-refractory disease and CD30 overexpression were enrolled. The patients received treatment with brentuximab vedotin, initially administered at doses of 1.8 or 2.4 mg/kg every 3 weeks. Assessment of treatment response was conducted after cycles 2 and 4, and subsequently after every four cycles. Two patients had an objective response to the treatment. One patient exhibited a sustained complete response while the other had a partial response [54]. In a separate study, a group of nine patients with CD30-positive GCTs were treated with brentuximab vedotin. Among them, 11.1% of the patients had progression-free survival (PFS) of 3 months, while 85.7% of the patients achieved 6-month overall survival (OS)) [55]. Recently, a phase II one arm study enrolling 18 patients investigated brentuximab vedotin in CD30-positive and CD30-negative/unknown patients [56]. No partial or complete responses were observed. Out of the 18 patients who participated in the study, six of them had stable disease. Among the six patients with stable disease, five had elevated levels of AFP or hCG at the beginning of the trial. However, all five patients had an initial decline of more than 50% in AFP or hCG levels that started to rise again at the time of disease progression. Two of the six patients belonged to the CD30 positive group, while the remaining four were in the CD30 negative group. Out of the 12 remaining patients, 10 experienced progressive disease as their best response. Two patients, one from the CD30 positive group and one from the CD30 negative group died before the first disease re-evaluation. Median progression-free survival (PFS) in the CD30-positive group was 1.2 months and 1.4 months in the CD30-negative group. Median overall survival (OS) was 2.5 and 5 months in the CD30-positive and CD30-negative groups, respectively [56].
What the sources say
- Disputedcites [56] Ashkar, 2021, Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors, Investig. New Drugs sourceExperimental — accuracy not yet measured
The Efficacy section reports median OS of 5.9 months in the CD30-negative cohort, not 5 months. The citing sentence's 2.5-month figure for the CD30-positive cohort matches the paper, but the claim about the CD30-negative cohort does not. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A recent immunohistochemical analysis of seminoma samples revealed the overexpression of several immune checkpoint receptors in the cancerous cells.”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 5. Immunotherapy in TGCTs > 5.3. Emerging Immunotherapeutic Targets
What the sources say
- Disputedcites [57] Hinsch, 2019, Expression of the Immune Checkpoint Receptor TIGIT in Seminoma, Oncol. Lett. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report TIGIT and PD-1 staining in immune cells within all 78 seminomas, not overexpression in the cancerous cells. The Introduction likewise says the study examined these receptors on lymphocytes. The claim assigns the finding to the wrong cell type. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19].”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 3. The Immune Landscape of TGCTs Testicular tissue is characterized as an immune-privileged site. In order to promote spermatogenesis and avoid autoimmune attack against germ cells, immune suppression must take place. However, this immune suppression has to be in balance with the activation of the immune response that aims to fight infection, trauma, cancer and conditions resulting in tissue damage [15]. In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19]. Immune response against malignant cells is mediated by immune cells and cytokines. Various studies have revealed different immunological patterns in patients with germ cell neoplasia (GCN) or in situ germ cell neoplasia (GCNIS) compared to men with normal testicular tissue or inflammatory lesions related to hypospermatogenesis. In patients with testicular tumors, B-cells and dendritic cells are abundant in TME, while T cells are present in both malignant and normal tissue. In addition to infiltrating immune cells, increased transcript levels of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α, anti-inflammatory cytokines (TGF-β1), Th1-driven cytokines (IL-2 and IFN-γ) and chemokines (CXCL-13, CXCL-10 and CCL-5) are found in patients with testicular tumors [20]. Moreover, recent studies have confirmed the significant effect of the interaction between malignant cells and TME on the modulation of the immune microenvironment. The crosstalk between malignant cells and TME leads to the overexpression of extracellular matrix proteins such as collagen I/IV and fibronectin, resulting in the elevated adhesive and migratory capacity of GCT cells. Most importantly, cisplatin sensitivity was found to be decreased in these patients [21]. Based on these observations of the alterations of the immune microenvironment of TGCTs and the availability of ICIs as the therapeutic option in other malignancies, a number of studies focused on evaluating novel immune biomarkers that could be differentially expressed between tumor and normal counterparts. The immune checkpoint PD-L1 is one of the regulators of immune response to tumor cells, and the PD-1/PD-L1 pathway has an immunosuppressive effect that helps promote carcinogenesis [22]. While PD-L1 expression is absent in normal tissue and GCNIS lesions, it is upregulated in GCN lesions [23]. PD-L1 is overexpressed in patients with GCN (76% of seminomas and 89% of non-seminomas) compared to normal testicular tissue [24]. Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23]. With regard to histological subtypes, PD-L1 overexpression was found to be most pronounced in patients with choriocarcinomas, while decreased in embryonal carcinoma, teratoma and yolk sack tumors, with the lowest expression observed in seminomas [24]. Besides the differential expression of immune markers which is fundamental to establishing a potential specific effect of targeted therapies, identifying the prognostic or/and predictive surrogate markers in the trajectory of testicular tumors treated with immunotherapy is important. Indeed, expression of the programmed death receptor axis (PD-1/PD-L1) was found to have prognostic value in TGCTs, being associated with progression-free survival (PFS) and overall survival (OS). High PD-L1 expression is a harbinger of poor prognostic features, including non-seminomatous histology, increased number of metastatic sites, high serum tumor markers and the presence non-pulmonary visceral metastases, whereas low PD-L1 expression is associated with longer PFS and OS [24]. Besides PD-L1 overexpression in testicular tumor cells, microarray-based analyses revealed the abundance of PD-1-positive tumor infiltrating T cells, also known as TILs. Peri-tumoral migration of these PD-1-positive infiltrating cells in testicular tissue containing GCN is facilitated by angiogenic signaling through the VEGFR2 receptor [25]. TILs are an important TME component, and their activity depends on immune checkpoint regulators such as V-domain Ig suppressor of T cell activation (VISTA) and PD-1/PD-L1 axis. In this context, a study by Chovanec et al. revealed that patients with GCN and abundant PD-L1 (+) TILs in the TME had significantly better outcomes than patients with lower expression [26]. The notion that the ability of testicular cancer cells to escape the immune system leading to disease dissemination is linked to reduced PD-L1 expression on TILs is further supported by a notable association between decreased PD-L1 expression in TILs and the presence of high-risk disease as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) [26]. Siska et al. [27] also investigated the significance of the PD-1/PD-L1 signaling pathway in the immune escape of testicular cancer. They used multiplexed fluorescence immunohistochemistry (FIHC) to analyze T-cell subsets, immune checkpoints, and targeted gene expression profiling, aiming to comprehensively understand the composition of immune infiltrates. Their findings revealed the presence and favorable prognostic utility of activated CD3+ T-cell infiltration, PD-L1 overexpression, and increased spatial interaction between PD-1 and PD-L1 in seminomas [27]. Conversely, non-seminomas exhibited elevated gene signatures associated with neutrophils and macrophages. Advanced stages of the disease, regardless of the histological tumor type, were characterized by reduced T-cell and NK-cell signatures, while Treg, neutrophil, mast cell, and macrophage signatures were elevated in these cases [27]. Combined PD-L1 and VISTA overexpression is particularly found in patients with choriocarcinoma components. Notably, 37.22% of patients exhibited high VISTA expression, while 49.44% showed high PD-L1 expression in a recent study. Conversely, a small percentage of seminoma patients (7.2%) had complete absence of PD-L1, as did 3.6% of men with non-seminomatous embryonal (NSE) tumors. Mixed tumors, teratomas or areas containing teratomas displayed very weak or no expression of immune checkpoints, with PD-L1 levels below 5% and VISTA cell positivity below 5% [28]. Low VISTA expression in tumor-associated immune cells was associated with shorter progression-free and overall survival [28]. Besides PD-L1 overexpression in GCN, the immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is also highly expressed in TILs regardless of the histological TGCT type, while the expression of CTLA-4 in tumor cells is predominantly found in yolk sack tumors, choriocarcinomas, and teratomas [27]. When jointly assessed, the level of PD-L1 expression displays no significant differences between seminomas and non-seminomas, although it is more abundant in choriocarcinomas than teratomas [29]. Additional studies have examined the expression of PD-L1 and CTLA-4 in tumor-associated macrophages (TAMs). In cases where tumor cells do not express PD-L1, there is often an overexpression of PD-L1 in TAMs. In this context, seminomas exhibit a higher presence of PD-L1+ TAMs within the tumor compared to non-seminoma TGCTs [30]. Regarding prognosis, the absence of PD-L1 positivity in immune cells is associated with worse relapse-free survival (RFS), while overexpression of CTLA-4 was correlated with good prognostic features such as the absence of lymphovascular invasion and lower pT and N stages [29]. Accumulating evidence suggests that not only the tumoral immune cell infiltration but also the proportion of lymphocytes relative to other immune cell types in the peripheral blood may be associated with the prognosis for these patients. Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31,32,33,34,35]. SII and the other systemic inflammatory markers were characterized as independent prognostic predictors for OS in addition to the IGCCCG risk group classification [33]. However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34]. Furthermore, although the levels of SII may serve as an independent prognostic indicator for progression-free survival (PFS) and overall survival (OS), when combined with PD-L1 expression on TILs, they can further stratify patients into three distinct prognostic groups [32]. The best prognosis is seen in patients with a high expression of PD-L1 in TILs and a low SII (SII < 1003) with a 5-year PFS and OS of 100%, while the worst prognosis is experienced by patients with a low expression of PDL1 in TILs and high SII (SII ≥ 1003), with a 5-year PFS and OS of 70% and 70%, respectively. Patients with combinations of high/high or low/low SII and PD-L1 in TILs have an intermediate prognosis [32].
What the sources say
- Not checked — no full text of the sourcecites [16] Mourah, 2014, EMMPRIN/CD147-Encriched Membrane Vesicles Released from Malignant Human Testicular Germ Cells Increase MMP Production through Tumor–Stroma Interaction, Biochim. Et Biophys. Acta (BBA)-General. Subj. source
- Partly supportedcites [17] Kozlova, 2020, The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers, Trends Pharmacol. Sci. sourceExperimental — accuracy not yet measured
The “Immune cells and the TME” section describes how tumor-cell and stromal signals recruit immunosuppressive cells, supporting the general link between tumor–microenvironment interactions and disrupted immune responses. It does not establish that link specifically in TGCTs; the searches for TGCTs and testicular germ cell tumors found no such discussion in our copy. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [18] Anderson, 2020, The Tumor Microenvironment, Curr. Biol. source
- Partly supportedcites [19] Skowron, 2021, Molecular and Epigenetic Pathogenesis of Germ Cell Tumors, Asian J. Urol. sourceExperimental — accuracy not yet measured
The section “The influence of microenvironment on TGCT pathogenesis” (page unavailable) describes a pro-inflammatory milieu in GCNIS and seminoma and suggests that it may favor TGCT development. The Conclusion (page unavailable) also identifies immune cells and inflammatory signals in the TGCT microenvironment. Neither passage says that interactions between malignant cells and the microenvironment disrupt immune balance. (LLM, conf=0.83)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23].”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 3. The Immune Landscape of TGCTs Testicular tissue is characterized as an immune-privileged site. In order to promote spermatogenesis and avoid autoimmune attack against germ cells, immune suppression must take place. However, this immune suppression has to be in balance with the activation of the immune response that aims to fight infection, trauma, cancer and conditions resulting in tissue damage [15]. In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19]. Immune response against malignant cells is mediated by immune cells and cytokines. Various studies have revealed different immunological patterns in patients with germ cell neoplasia (GCN) or in situ germ cell neoplasia (GCNIS) compared to men with normal testicular tissue or inflammatory lesions related to hypospermatogenesis. In patients with testicular tumors, B-cells and dendritic cells are abundant in TME, while T cells are present in both malignant and normal tissue. In addition to infiltrating immune cells, increased transcript levels of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α, anti-inflammatory cytokines (TGF-β1), Th1-driven cytokines (IL-2 and IFN-γ) and chemokines (CXCL-13, CXCL-10 and CCL-5) are found in patients with testicular tumors [20]. Moreover, recent studies have confirmed the significant effect of the interaction between malignant cells and TME on the modulation of the immune microenvironment. The crosstalk between malignant cells and TME leads to the overexpression of extracellular matrix proteins such as collagen I/IV and fibronectin, resulting in the elevated adhesive and migratory capacity of GCT cells. Most importantly, cisplatin sensitivity was found to be decreased in these patients [21]. Based on these observations of the alterations of the immune microenvironment of TGCTs and the availability of ICIs as the therapeutic option in other malignancies, a number of studies focused on evaluating novel immune biomarkers that could be differentially expressed between tumor and normal counterparts. The immune checkpoint PD-L1 is one of the regulators of immune response to tumor cells, and the PD-1/PD-L1 pathway has an immunosuppressive effect that helps promote carcinogenesis [22]. While PD-L1 expression is absent in normal tissue and GCNIS lesions, it is upregulated in GCN lesions [23]. PD-L1 is overexpressed in patients with GCN (76% of seminomas and 89% of non-seminomas) compared to normal testicular tissue [24]. Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23]. With regard to histological subtypes, PD-L1 overexpression was found to be most pronounced in patients with choriocarcinomas, while decreased in embryonal carcinoma, teratoma and yolk sack tumors, with the lowest expression observed in seminomas [24]. Besides the differential expression of immune markers which is fundamental to establishing a potential specific effect of targeted therapies, identifying the prognostic or/and predictive surrogate markers in the trajectory of testicular tumors treated with immunotherapy is important. Indeed, expression of the programmed death receptor axis (PD-1/PD-L1) was found to have prognostic value in TGCTs, being associated with progression-free survival (PFS) and overall survival (OS). High PD-L1 expression is a harbinger of poor prognostic features, including non-seminomatous histology, increased number of metastatic sites, high serum tumor markers and the presence non-pulmonary visceral metastases, whereas low PD-L1 expression is associated with longer PFS and OS [24]. Besides PD-L1 overexpression in testicular tumor cells, microarray-based analyses revealed the abundance of PD-1-positive tumor infiltrating T cells, also known as TILs. Peri-tumoral migration of these PD-1-positive infiltrating cells in testicular tissue containing GCN is facilitated by angiogenic signaling through the VEGFR2 receptor [25]. TILs are an important TME component, and their activity depends on immune checkpoint regulators such as V-domain Ig suppressor of T cell activation (VISTA) and PD-1/PD-L1 axis. In this context, a study by Chovanec et al. revealed that patients with GCN and abundant PD-L1 (+) TILs in the TME had significantly better outcomes than patients with lower expression [26]. The notion that the ability of testicular cancer cells to escape the immune system leading to disease dissemination is linked to reduced PD-L1 expression on TILs is further supported by a notable association between decreased PD-L1 expression in TILs and the presence of high-risk disease as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) [26]. Siska et al. [27] also investigated the significance of the PD-1/PD-L1 signaling pathway in the immune escape of testicular cancer. They used multiplexed fluorescence immunohistochemistry (FIHC) to analyze T-cell subsets, immune checkpoints, and targeted gene expression profiling, aiming to comprehensively understand the composition of immune infiltrates. Their findings revealed the presence and favorable prognostic utility of activated CD3+ T-cell infiltration, PD-L1 overexpression, and increased spatial interaction between PD-1 and PD-L1 in seminomas [27]. Conversely, non-seminomas exhibited elevated gene signatures associated with neutrophils and macrophages. Advanced stages of the disease, regardless of the histological tumor type, were characterized by reduced T-cell and NK-cell signatures, while Treg, neutrophil, mast cell, and macrophage signatures were elevated in these cases [27]. Combined PD-L1 and VISTA overexpression is particularly found in patients with choriocarcinoma components. Notably, 37.22% of patients exhibited high VISTA expression, while 49.44% showed high PD-L1 expression in a recent study. Conversely, a small percentage of seminoma patients (7.2%) had complete absence of PD-L1, as did 3.6% of men with non-seminomatous embryonal (NSE) tumors. Mixed tumors, teratomas or areas containing teratomas displayed very weak or no expression of immune checkpoints, with PD-L1 levels below 5% and VISTA cell positivity below 5% [28]. Low VISTA expression in tumor-associated immune cells was associated with shorter progression-free and overall survival [28]. Besides PD-L1 overexpression in GCN, the immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is also highly expressed in TILs regardless of the histological TGCT type, while the expression of CTLA-4 in tumor cells is predominantly found in yolk sack tumors, choriocarcinomas, and teratomas [27]. When jointly assessed, the level of PD-L1 expression displays no significant differences between seminomas and non-seminomas, although it is more abundant in choriocarcinomas than teratomas [29]. Additional studies have examined the expression of PD-L1 and CTLA-4 in tumor-associated macrophages (TAMs). In cases where tumor cells do not express PD-L1, there is often an overexpression of PD-L1 in TAMs. In this context, seminomas exhibit a higher presence of PD-L1+ TAMs within the tumor compared to non-seminoma TGCTs [30]. Regarding prognosis, the absence of PD-L1 positivity in immune cells is associated with worse relapse-free survival (RFS), while overexpression of CTLA-4 was correlated with good prognostic features such as the absence of lymphovascular invasion and lower pT and N stages [29]. Accumulating evidence suggests that not only the tumoral immune cell infiltration but also the proportion of lymphocytes relative to other immune cell types in the peripheral blood may be associated with the prognosis for these patients. Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31,32,33,34,35]. SII and the other systemic inflammatory markers were characterized as independent prognostic predictors for OS in addition to the IGCCCG risk group classification [33]. However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34]. Furthermore, although the levels of SII may serve as an independent prognostic indicator for progression-free survival (PFS) and overall survival (OS), when combined with PD-L1 expression on TILs, they can further stratify patients into three distinct prognostic groups [32]. The best prognosis is seen in patients with a high expression of PD-L1 in TILs and a low SII (SII < 1003) with a 5-year PFS and OS of 100%, while the worst prognosis is experienced by patients with a low expression of PDL1 in TILs and high SII (SII ≥ 1003), with a 5-year PFS and OS of 70% and 70%, respectively. Patients with combinations of high/high or low/low SII and PD-L1 in TILs have an intermediate prognosis [32].
What the sources say
- Partly supportedcites [23] Fankhauser, 2015, Frequent PD-L1 Expression in Testicular Germ Cell Tumors, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Results (page not available) report PD-L1 positivity of 53% in pT1, 66% in pT2, and 70% in pT3 tumors, matching the cited figures. They do not report that the differences between stages are statistically significant, so the claim of “significant overexpression” is unsupported. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34].”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 3. The Immune Landscape of TGCTs Testicular tissue is characterized as an immune-privileged site. In order to promote spermatogenesis and avoid autoimmune attack against germ cells, immune suppression must take place. However, this immune suppression has to be in balance with the activation of the immune response that aims to fight infection, trauma, cancer and conditions resulting in tissue damage [15]. In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19]. Immune response against malignant cells is mediated by immune cells and cytokines. Various studies have revealed different immunological patterns in patients with germ cell neoplasia (GCN) or in situ germ cell neoplasia (GCNIS) compared to men with normal testicular tissue or inflammatory lesions related to hypospermatogenesis. In patients with testicular tumors, B-cells and dendritic cells are abundant in TME, while T cells are present in both malignant and normal tissue. In addition to infiltrating immune cells, increased transcript levels of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α, anti-inflammatory cytokines (TGF-β1), Th1-driven cytokines (IL-2 and IFN-γ) and chemokines (CXCL-13, CXCL-10 and CCL-5) are found in patients with testicular tumors [20]. Moreover, recent studies have confirmed the significant effect of the interaction between malignant cells and TME on the modulation of the immune microenvironment. The crosstalk between malignant cells and TME leads to the overexpression of extracellular matrix proteins such as collagen I/IV and fibronectin, resulting in the elevated adhesive and migratory capacity of GCT cells. Most importantly, cisplatin sensitivity was found to be decreased in these patients [21]. Based on these observations of the alterations of the immune microenvironment of TGCTs and the availability of ICIs as the therapeutic option in other malignancies, a number of studies focused on evaluating novel immune biomarkers that could be differentially expressed between tumor and normal counterparts. The immune checkpoint PD-L1 is one of the regulators of immune response to tumor cells, and the PD-1/PD-L1 pathway has an immunosuppressive effect that helps promote carcinogenesis [22]. While PD-L1 expression is absent in normal tissue and GCNIS lesions, it is upregulated in GCN lesions [23]. PD-L1 is overexpressed in patients with GCN (76% of seminomas and 89% of non-seminomas) compared to normal testicular tissue [24]. Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23]. With regard to histological subtypes, PD-L1 overexpression was found to be most pronounced in patients with choriocarcinomas, while decreased in embryonal carcinoma, teratoma and yolk sack tumors, with the lowest expression observed in seminomas [24]. Besides the differential expression of immune markers which is fundamental to establishing a potential specific effect of targeted therapies, identifying the prognostic or/and predictive surrogate markers in the trajectory of testicular tumors treated with immunotherapy is important. Indeed, expression of the programmed death receptor axis (PD-1/PD-L1) was found to have prognostic value in TGCTs, being associated with progression-free survival (PFS) and overall survival (OS). High PD-L1 expression is a harbinger of poor prognostic features, including non-seminomatous histology, increased number of metastatic sites, high serum tumor markers and the presence non-pulmonary visceral metastases, whereas low PD-L1 expression is associated with longer PFS and OS [24]. Besides PD-L1 overexpression in testicular tumor cells, microarray-based analyses revealed the abundance of PD-1-positive tumor infiltrating T cells, also known as TILs. Peri-tumoral migration of these PD-1-positive infiltrating cells in testicular tissue containing GCN is facilitated by angiogenic signaling through the VEGFR2 receptor [25]. TILs are an important TME component, and their activity depends on immune checkpoint regulators such as V-domain Ig suppressor of T cell activation (VISTA) and PD-1/PD-L1 axis. In this context, a study by Chovanec et al. revealed that patients with GCN and abundant PD-L1 (+) TILs in the TME had significantly better outcomes than patients with lower expression [26]. The notion that the ability of testicular cancer cells to escape the immune system leading to disease dissemination is linked to reduced PD-L1 expression on TILs is further supported by a notable association between decreased PD-L1 expression in TILs and the presence of high-risk disease as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) [26]. Siska et al. [27] also investigated the significance of the PD-1/PD-L1 signaling pathway in the immune escape of testicular cancer. They used multiplexed fluorescence immunohistochemistry (FIHC) to analyze T-cell subsets, immune checkpoints, and targeted gene expression profiling, aiming to comprehensively understand the composition of immune infiltrates. Their findings revealed the presence and favorable prognostic utility of activated CD3+ T-cell infiltration, PD-L1 overexpression, and increased spatial interaction between PD-1 and PD-L1 in seminomas [27]. Conversely, non-seminomas exhibited elevated gene signatures associated with neutrophils and macrophages. Advanced stages of the disease, regardless of the histological tumor type, were characterized by reduced T-cell and NK-cell signatures, while Treg, neutrophil, mast cell, and macrophage signatures were elevated in these cases [27]. Combined PD-L1 and VISTA overexpression is particularly found in patients with choriocarcinoma components. Notably, 37.22% of patients exhibited high VISTA expression, while 49.44% showed high PD-L1 expression in a recent study. Conversely, a small percentage of seminoma patients (7.2%) had complete absence of PD-L1, as did 3.6% of men with non-seminomatous embryonal (NSE) tumors. Mixed tumors, teratomas or areas containing teratomas displayed very weak or no expression of immune checkpoints, with PD-L1 levels below 5% and VISTA cell positivity below 5% [28]. Low VISTA expression in tumor-associated immune cells was associated with shorter progression-free and overall survival [28]. Besides PD-L1 overexpression in GCN, the immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is also highly expressed in TILs regardless of the histological TGCT type, while the expression of CTLA-4 in tumor cells is predominantly found in yolk sack tumors, choriocarcinomas, and teratomas [27]. When jointly assessed, the level of PD-L1 expression displays no significant differences between seminomas and non-seminomas, although it is more abundant in choriocarcinomas than teratomas [29]. Additional studies have examined the expression of PD-L1 and CTLA-4 in tumor-associated macrophages (TAMs). In cases where tumor cells do not express PD-L1, there is often an overexpression of PD-L1 in TAMs. In this context, seminomas exhibit a higher presence of PD-L1+ TAMs within the tumor compared to non-seminoma TGCTs [30]. Regarding prognosis, the absence of PD-L1 positivity in immune cells is associated with worse relapse-free survival (RFS), while overexpression of CTLA-4 was correlated with good prognostic features such as the absence of lymphovascular invasion and lower pT and N stages [29]. Accumulating evidence suggests that not only the tumoral immune cell infiltration but also the proportion of lymphocytes relative to other immune cell types in the peripheral blood may be associated with the prognosis for these patients. Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31,32,33,34,35]. SII and the other systemic inflammatory markers were characterized as independent prognostic predictors for OS in addition to the IGCCCG risk group classification [33]. However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34]. Furthermore, although the levels of SII may serve as an independent prognostic indicator for progression-free survival (PFS) and overall survival (OS), when combined with PD-L1 expression on TILs, they can further stratify patients into three distinct prognostic groups [32]. The best prognosis is seen in patients with a high expression of PD-L1 in TILs and a low SII (SII < 1003) with a 5-year PFS and OS of 100%, while the worst prognosis is experienced by patients with a low expression of PDL1 in TILs and high SII (SII ≥ 1003), with a 5-year PFS and OS of 70% and 70%, respectively. Patients with combinations of high/high or low/low SII and PD-L1 in TILs have an intermediate prognosis [32].
What the sources say
- Supportedcites [34] Ribnikar, 2021, The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer, Curr. Oncol. source
The Discussion (§4) states that elevated NLR was associated with adverse PFS and OS, but not independently of IGCCCG risk classification. The Conclusions (§5) repeat this finding for patients with metastatic germ-cell tumors receiving first-line chemotherapy. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
102 more claims · 54 with their cited sources checked
Create a free account to see all 146 claims and to verify the 20 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 26
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > Abstract > Simple Summary
“One-fifth of patients with advanced testicular germ cell tumors (TGCTs) develop platinum-refractory disease.”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > Abstract
“However, approximately 15% of the patients develop platinum-refractory disease and suffer multiple relapses.”
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“This systematic review was conducted according to the criteria included in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13,14].”
MethodPage, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262 · cited 1×
“This systematic review was conducted according to the criteria included in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13,14].”
MethodAnderson, N. M., & Simon, M. C. (2020) · Current Biology · doi:10.1016/j.cub.2020.06.081 · Cited by 2,718
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246 · cited 1×
“Additionally, it may assist in promoting cancer cell apoptosis and the proliferation of antigen-specific T cells, while simultaneously inducing apoptosis in T-regulatory cells [38].”
BackgroundTim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856 · cited 1×
“Furthermore, T-cell immunoglobulin and mucin domain-3 (TIM-3) have been identified as important immunoreceptors involved in T-cell exhaustion, leading to the inactivation of these cells [58].”
BackgroundThe testis in immune privilege
Fijak, M., & Meinhardt, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00438.x · Cited by 483 · cited 1×
“However, this immune suppression has to be in balance with the activation of the immune response that aims to fight infection, trauma, cancer and conditions resulting in tissue damage [15].”
BackgroundTesticular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450 · cited 1×
“Testicular germ cell tumors (TGCTs) are the most common malignancy among men between 20 and 40 years of age, with a rising incidence [1].”
BackgroundCognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity
Smith, C. M., Wilson, N. S., Waithman, J., Villadangos, J. A., Carbone, F. R., Heath, W. R., & Belz, G. T. (2004) · Nature Immunology · doi:10.1038/ni1129 · Cited by 448 · cited 1×
“MDSCs and Tregs are characterized by an immune inhibitory potential, whereas differentiated dendritic cells support antigen presentation and play a pivotal role in initiating the adaptive immune response [44].”
BackgroundRajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
Cited by
Udvorková, N., Fekiačová, A., Majtánová, K., Mego, M., & Kučerová, L. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00200.2024 · Cited by 8
Mehr, F. K., Emtiazi, N., & Zolfi, E. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103169 · Cited by 6
Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors
Sperber, L., von Brandenstein, M., Kessler, C., Heidenreich, J., Storz, E., Pfister, D. G., Paffenholz, P., Tolkach, Y., Bernhardt, M., Wirtz, R., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06325-4 · Cited by 3
“…often seen in CC. SG exhibits strong cytotoxicity in TROP2-pos-itive, chemotherapy-resistant GCT cells; however, its clini - cal effectiveness still needs to be confirmed. due to the low tumor mutational burden and the lack of effective biomarker-based patient selection (Evmorfopoulos et al. 2024).”
Zhao, H., Liu, W., Xu, H., Wang, L., Chen, Z., Sun, Y., & Wang, L. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04374-3 · Cited by 3
“This enrichment aligns with the distinct immunobi-ology of these malignancies: TGCTs are characterized by intense lymphocytic infiltration[29], THYM is intrinsically linked to T-cell development[30], and BRCA is shaped by continuous immunosurveillance mechanisms [31].”
Decoding testicular germ cell tumors: integrating risk, biology, and biomarkers into future care
Bowling, G. C., Lacson, J. C. A., Almeida, A. A., Rhee, J., Chesnut, G. T., Nichols, C. R., & Kern, S. Q. (2026) · Gene · doi:10.1016/j.gene.2026.150044 · Cited by 2
Metadata
- Authors
- Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J.
- Affiliations
- University of Thessaly (GR)
- Aberdeen Royal Infirmary (GB)
- Corresponding author
- Vlachostergios, Panagiotis J.
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-01-19
- Volume
- 16
- Issue
- 2
- Pages
- 428
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10814346
- OpenAlex
- W4391029848
- Cited by
- 11
- References
- 83
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- testicular germ cell tumors, platinum-refractory disease, immune microenvironment, immune checkpoint inhibitors, PD-1/PD-L1 axis, anti-CTLA-4 monoclonal antibody, antibody-drug conjugates, cancer vaccines, tyrosine kinase inhibitors, CAR T-cell therapy, immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors. https://app.cochat.ai/papers/10.3390/cancers16020428
- The paper
- Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024). The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors. Cancers. https://doi.org/10.3390/cancers16020428
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
